Olema Pharmaceuticals, Inc. reported a net loss of $162.5 million for the year ended December 31, 2025, compared to a net loss of $129.5 million for the previous year. The increased loss was primarily driven by higher research and development expenses as the company advanced its clinical programs. As of December 31, 2025, Olema had cash, cash equivalents, and marketable securities totaling $505.4 million.
Research and development expenses for 2025 totaled $157.7 million, up from $124.5 million in 2024. This increase was mainly due to increased spending on clinical operations and development-related activities for palazestrant and OP-3136, a $5.0 million increase in a milestone payment to Aurigene, and higher personnel-related costs. These increases were partially offset by a $4.4 million decrease in non-cash stock-based compensation expense. General and administrative expenses also increased to $21.0 million in 2025 from $17.7 million in 2024, primarily due to higher corporate-related costs and personnel-related costs.
Key operational developments for Olema in 2025 included the ongoing Phase 3 clinical trial (OPERA-02) of palazestrant in combination with ribociclib, supported by a clinical trial collaboration and supply agreement with Novartis. Novartis is providing ribociclib drug supply for the trial. Olema also continued to advance OP-3136, with initial clinical data expected in the second quarter of 2026. The company initiated a Phase 1b/2 clinical study evaluating palazestrant in combination with everolimus. In September 2025, Olema announced a new clinical trial collaboration and supply agreement with Pfizer to evaluate palazestrant plus atirmociclib in patients with ER+/HER2- metastatic breast cancer.
Looking ahead, Olema anticipates top-line results from the OPERA-01 trial in the fall of 2026, with a potential NDA submission in 2027 and FDA approval and commercial launch in late 2027. Top-line data from the OPERA-02 trial is expected in 2028, with potential FDA approval and commercial launch in 2029. The company expects its cash, cash equivalents, and marketable securities as of December 31, 2025, as well as the available balance under its credit facility, will enable it to fund its current operating plan through mid-2028. Olema will continue to explore opportunities to acquire products and technologies that align with its core areas of expertise and complement its existing portfolio.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for endocrine-driven cancers, primarily breast cancer. Its lead candidate, palazestrant, is an oral CERAN/SERD designed to treat ER+ breast cancers, with ongoing late-stage clinical trials. The company also develops OP-3136, a KAT6 inhibitor, aiming to address resistance mechanisms. Olema collaborates with major pharma partners to advance innovative, potentially superior endocrine treatments.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.